KR20180086257A - 환자에서 전이 암의 효과적인 치료를 위한 병용요법 - Google Patents

환자에서 전이 암의 효과적인 치료를 위한 병용요법 Download PDF

Info

Publication number
KR20180086257A
KR20180086257A KR1020187019041A KR20187019041A KR20180086257A KR 20180086257 A KR20180086257 A KR 20180086257A KR 1020187019041 A KR1020187019041 A KR 1020187019041A KR 20187019041 A KR20187019041 A KR 20187019041A KR 20180086257 A KR20180086257 A KR 20180086257A
Authority
KR
South Korea
Prior art keywords
cancer
ascorbic acid
drug
dose
grams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187019041A
Other languages
English (en)
Korean (ko)
Inventor
아놀드 글라지어
Original Assignee
제네럴 온콜로지, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제네럴 온콜로지, 인코포레이티드 filed Critical 제네럴 온콜로지, 인코포레이티드
Publication of KR20180086257A publication Critical patent/KR20180086257A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187019041A 2015-12-07 2016-12-06 환자에서 전이 암의 효과적인 치료를 위한 병용요법 Ceased KR20180086257A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263880P 2015-12-07 2015-12-07
US62/263,880 2015-12-07
PCT/US2016/065079 WO2017100162A1 (en) 2015-12-07 2016-12-06 Combination for the effective treatment of metastatic cancer in patients

Publications (1)

Publication Number Publication Date
KR20180086257A true KR20180086257A (ko) 2018-07-30

Family

ID=57708742

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187019041A Ceased KR20180086257A (ko) 2015-12-07 2016-12-06 환자에서 전이 암의 효과적인 치료를 위한 병용요법

Country Status (14)

Country Link
US (3) US11154520B2 (enExample)
EP (1) EP3386546B1 (enExample)
JP (3) JP6831853B2 (enExample)
KR (1) KR20180086257A (enExample)
AU (2) AU2016367112B2 (enExample)
CA (1) CA3044959C (enExample)
DK (1) DK3386546T3 (enExample)
ES (1) ES2994931T3 (enExample)
FI (1) FI3386546T3 (enExample)
HU (1) HUE069668T2 (enExample)
IL (2) IL290251B2 (enExample)
PL (1) PL3386546T3 (enExample)
PT (1) PT3386546T (enExample)
WO (1) WO2017100162A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3721878A1 (en) 2012-10-22 2020-10-14 Arnold Glazier Methods for the effective treatment of metastatic cancer
US11298338B2 (en) * 2016-06-06 2022-04-12 University Of Iowa Research Foundation Compositions and methods for cancer therapy
EP3840744B1 (en) 2018-08-21 2025-06-04 Board of Regents, The University of Texas System Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress
CN114904011B (zh) * 2021-07-06 2023-10-13 中国科学院上海硅酸盐研究所 非铁基谷胱甘肽消耗协同活性氧物种增强复合材料及其制备方法和应用
EP4376822A4 (en) * 2021-07-29 2025-09-17 Lantern Pharma Inc TREATMENT OF CANCER WITH COMBINATIONS OF PARP INHIBITORS AND ACYLFULVENS
CN116407557A (zh) * 2023-05-29 2023-07-11 四川大学华西医院 一种防治出血性脑卒中的药物组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305873C (en) * 1987-05-26 1992-08-04 Howel Gwynne Giles Method and means for detecting alcohol levels in humans
US5639787A (en) 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
CA2371728C (en) 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
EP1313508B1 (en) * 2000-06-30 2007-04-18 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
ES2303588T3 (es) 2002-03-22 2008-08-16 Ludwig Maximilians Universitat Ensayo de citocapacidad.
ES2421516T3 (es) 2002-11-06 2013-09-03 Dana Farber Cancer Inst Inc Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
US20090123447A1 (en) * 2007-11-14 2009-05-14 The Regents Of The University Of California Compositions and methods to inhibit rna viral reproduction
EP2456306A4 (en) * 2009-07-20 2012-12-26 Summa Health System VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING OESTOLYSIS OR EXTENDING A PROTEST IMPLANT
EP3721878A1 (en) 2012-10-22 2020-10-14 Arnold Glazier Methods for the effective treatment of metastatic cancer

Also Published As

Publication number Publication date
EP3386546A1 (en) 2018-10-17
US20220096405A1 (en) 2022-03-31
AU2022200131A1 (en) 2022-02-10
JP6831853B2 (ja) 2021-02-17
PL3386546T3 (pl) 2025-01-27
IL259512B2 (en) 2024-03-01
JP2019501962A (ja) 2019-01-24
FI3386546T3 (fi) 2024-12-05
DK3386546T3 (en) 2024-11-25
IL259512B1 (en) 2023-11-01
US11154520B2 (en) 2021-10-26
PT3386546T (pt) 2024-12-09
JP7144554B2 (ja) 2022-09-29
CA3044959A1 (en) 2017-06-15
IL259512A (en) 2018-07-31
ES2994931T3 (en) 2025-02-04
IL290251B2 (en) 2024-07-01
CA3044959C (en) 2024-01-09
EP3386546B1 (en) 2024-09-04
IL290251A (en) 2022-04-01
JP2021073262A (ja) 2021-05-13
US20240216308A1 (en) 2024-07-04
AU2016367112A1 (en) 2018-07-12
HUE069668T2 (hu) 2025-04-28
IL290251B1 (en) 2024-03-01
JP2022171816A (ja) 2022-11-11
AU2016367112B2 (en) 2022-01-13
US20180338935A1 (en) 2018-11-29
WO2017100162A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
JP7144554B2 (ja) 患者における転移性癌の有効な治療のための組合せ
Traverso et al. Role of glutathione in cancer progression and chemoresistance
Ramsay et al. Glutathione S-conjugates as prodrugs to target drug-resistant tumors
Wenzel et al. ALDH-2 deficiency increases cardiovascular oxidative stress---Evidence for indirect antioxidative properties
Mocellin Nitric oxide: cancer target or anticancer agent?
Sharma et al. Site-directed delivery of nitric oxide to cancers
US20240024344A1 (en) Methods For The Effective Treatment Of Metastatic Cancer
Menna et al. Rethinking drugs from chemistry to therapeutic opportunities: pixantrone beyond anthracyclines
Ahmad Ganai et al. Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer
Borgini et al. Synthesis of Veliparib prodrugs and determination of drug-release-dependent PARP-1 inhibition
EP3181118A1 (en) Synergistic combination of txnr inhibitors and ascorbate for treatment of b cell malignancies
HK1261631A1 (en) Combination for the effective treatment of metastatic cancer in patients
Morales et al. Small-molecule inhibitors of glutathione S-transferase P1-1 as anticancer therapeutic agents
PT1694338E (pt) Utilização de miméticos da superóxido dismutase e de glutationa redutase sob a forma de fármacos anticancerosos
HK40039081A (en) Methods for the effective treatment of metastatic cancer
Aranalde Ferroptosis-Importance and Potential Effects in Hematological Malignancies
da Costa Cysteine, a Facilitator of Hypoxia Adaptation and a Promoter of Drug-Resistance: A New Route to Better Diagnose and Treat Ovarian Cancer Patients
Huxham The tumour microenvironment: mapping the microregional effects of drugs
Nunes Cysteine, a facilitator of hypoxia adaptation and a promoter of drug-resistance: a new route to better diagnose and treat ovarian cancer patients
McCrudden et al. Emerging Role of NO-Mediated Therapeutics
Moon In Vitro and In Vivo Studies of Chemotherapeutic Doxorubicin Analogs
Townsend et al. Redox Pathways as a Platform in Drug Development

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601